Table 1.
Key trials establishing modern Ewing sarcoma (EwS) treatment.
| Reference | Year of Publication | Chemotherapy Backbone Evaluated |
Trial Name | Key Findings |
|---|---|---|---|---|
| [219] | 2003 | VDC vs. VDC/IE | INT-0091 | Five-year EFS improved from 54% to 69% with the addition of IE to VDC for patients with localized EwS |
| [222] | 2003 | P6 (VDC/IE with augmented Cy) | MSK | Four-year EFS 82% for patients with localized EwS |
| [105] | 2009 | VDC/IE with augmented alkylator dosing vs. standard VDC/IE | INT-0154 | No improvement in outcomes with alkylator dose intensification |
| [223] | 2012 | IC-VDC/IE | AEWS0031 | Six-year EFS improved to 73% from 65% with interval compressed chemotherapy for localized EwS |
| [7] | 2018 | VAI vs. VAI/HD-BuMel | Euro-E.W.I.N.G. 99 and Ewing 2008 |
Eight-year EFS improved to 60.7% from 47.1% for localized high-risk EwS |
| [229] | 2019 | VDC/IE vs. VDC/IE/VTC | AEWS1031 | No benefit to the addition of VCT cycles for localized EwS |
| [232] | 2019 | VDC/IE vs. VDC/IE/ganitumab | AEWS1221 | No improvement in outcomes for metastatic EwS with the addition of ganitumab |
| [6] | 2019 | VIDE induction + VAI/VAC (or VIA/HD-BuMel) vs. VDC/IE induction + IE/VC (or VAI/HD-BuMel) |
EURO Ewing 2012 | VDC/IE induction was found on preliminary analysis to have superior PFS and OS compared to VIDE induction |
VDC, vincristine/doxorubicin/cyclophosphamide; IE, ifosfamide/etoposide; IC-VDC/IE, interval compressed VDC; VAI, vincristine/actinomycin D/ifosfamide; HD-BuMel, high-dose busulfan/melphalan and stem cell rescue; VCT, vincristine/cyclophosphamide/topotecan; VIDE, vincristine/ifosfamide/doxorubicin/etoposide; VAC, vincristine/actinomycin D/cyclophosphamide; VC, vincristine/cyclophosphamide.